Highlights in myasthenia gravis from AANEM 2024 include efficacy data on efgartigimod, ravulizumab, zilucoplan, and first-in-class inebilizumab, as well as safety outcomes in pregnancy for eculizumab.

Increased demands from an aging population and pandemic-related supply shortages leave provinces scrambling to allocate ...

First, there were “Ozempic babies.” Now, there is also Ozempic-before-baby. Unplanned pregnancies are still regularly being ...

Individuals at an increased risk of developing rheumatoid arthritis (RA) have a unique gut microbial composition, ...

The first pregnancy guideline updates from the American Thyroid Association since 2017 to emphasize shared decision-making, ...

In September this year in Rome, an older woman died, and her daughter spent a week in intensive care after eating a few ...

SAN ANTONIO — Several types of anti-obesity medications (AOMs), including glucagon-like peptide 1s (GLP-1s), are associated ...

Higher plasma levels of omega-6 and omega-3 fatty acids are associated with a lower incidence of cancer. However, omega-3 ...

The US Food and Drug Administration (FDA) sometimes allows cancer drugs with accelerated approvals to remain on the market ...

The use of semaglutide, a glucagon-like peptide 1 receptor agonist (GLP-1 RA), is not associated with an increased risk for ...

“Petechial rash often prompts further investigation into hematological, dermatological, or vasculitis causes. However, if the ...

PHILADELPHIA — Patients with celiac disease who take an angiotensin receptor blocker (ARB) may experience worse outcomes, ...